The Molecule That Moved a Country's GDP

On the last day of June 2025, Statistics Denmark published one of its routine revisions to the national accounts and gave it a headline that statistical offices do not usually write: low growth in the Danish economy without the pharmaceutical industry. The revision itself was large — cumulative growth across 2021 to 2024 was cut from 15.9 per cent to 11.4 — but the sentence that travelled was a counterfactual. Without the pharmaceutical industry's contribution, the office said, growth would have been negative in both 2022 and 2023 1.

That industry is dominated by one company, and the company's rise rests on one class of engineered peptide: the GLP-1 receptor agonists sold for type 2 diabetes and, from 2021, for obesity. This piece is about the economics of that rise — what it did to the growth figures, the currency and the public finances of a country of about six million people, and what happened when the company stumbled in 2025. The trials that created the demand, and the chemistry that made the molecule cheap enough to manufacture at scale, are told elsewhere on this site. Here the molecule matters only as the thing that was sold.

A headline statisticians do not usually write

Gross domestic product is a measure of value added by producers resident in a country. For most economies that is an unremarkable definition. For a small open economy that happens to host the owner of a patent-protected blockbuster, it becomes strange very quickly, because the international rules of national accounting attribute much of the value of a product to whoever owns the goods and the intellectual property behind them — even where a factory in another country did part of the physical work. A pen sold in a pharmacy thousands of miles away can show up, in large part, as Danish output.

That is why the Danish figures moved so much, and why they kept being rewritten. The same office that cut four years of cumulative growth by more than four percentage points in 2025 published estimates a year later putting growth at 3.9 per cent in 2024 and 3.5 per cent in 2025 2. None of this is error in the ordinary sense. It is what happens when one exceptionally profitable product, made and sold across dozens of jurisdictions, is poured into a framework built to count tonnes of steel and hours of labour in a single country.

The longer view is the clearest one. Between 2019 and 2025, Danish gross value added grew by 16.6 per cent; excluding the pharmaceutical industry it grew by 8.1 per cent, an average of 1.3 per cent a year against 2.6 per cent with it 2. Half of a decade's growth, in round terms, came from one sector — and inside that sector, from one family of molecules.

A company larger than its country

The image that fixed all this in the public mind arrived in September 2023, when the company's stock-market value, at around $418 billion, passed the International Monetary Fund's projection for Denmark's entire annual output that year, around $406 billion 6. The comparison is technically meaningless — one is a stock of expected future profits, the other a flow of one year's production — and it was repeated everywhere anyway, because it captured something real about proportion.

It is worth holding on to that distinction between a market value and an output figure, because it becomes the whole story in 2025. A market value is a collective guess about the future. The national accounts are a slow, revisable count of what actually happened. For most of 2023 and 2024 the two told the same story. When they stopped doing so, the gap between them turned out to be the most interesting thing about the episode.

Holding the krone down

Denmark does not run an independent currency in the usual sense. The krone has been pegged to the euro for decades, and the central bank's primary job is to keep it there, using two tools: buying and selling kroner in the currency market, and setting its policy rate a little above or below the European Central Bank's. When a Danish exporter earns euros or dollars and converts them, it buys kroner, and enough of that pushes the currency upward against the peg.

In February 2023, after a series of interventions, Danmarks Nationalbank widened the spread between its policy rate and the ECB's from −0.25 to −0.40 percentage points. It explained the move plainly: the krone had spent an extended period on the strong side of its central rate because Danish businesses' strong foreign earnings were being exchanged into kroner 3. The bank did not name a company, and did not need to.

The consequence is one of the stranger transmission channels in modern economics. A household in Aarhus with a variable-rate mortgage was, at one remove and in part, paying a slightly lower rate because people in other countries were buying a weekly injection. Currency pegs are designed to import another central bank's monetary policy. They are not designed for a single exporter large enough to lean on the peg by itself.

Where the money went, and where it did not

The more careful question is what a boom like this does to everybody else. In August 2024 Danmarks Nationalbank modelled an increase in pharmaceutical exports and found that consumption and output rise at first, but that the output gain is temporary and disappears once wages adjust. In the long run aggregate output is unchanged; what changes is where activity happens, between municipalities and between industries. The consumption gains, it found, were concentrated in North Zealand and around Kalundborg, the harbour town on the west coast of Zealand where much of the industry's production sits 4.

An IMF staff paper the same year reached a complementary conclusion from another direction. It found only weak correlations between productivity shocks at the company and growth in the wider economy, and between the company's productivity and that of other Danish firms, although there was evidence of spillover within the pharmaceutical industry itself. It also noted that the company's profits had contributed substantially to Denmark's budget surplus, which reinforced the dependence of the public finances on a narrow segment of one industry 5.

Put those findings together and the shape is clear. The boom was large, real and taxable, and it made the Danish state richer. It did not make the rest of the Danish economy much more productive, and much of its local effect was concentrated in a few places. A country can be carried by an industry without being transformed by it.

2025: the correction

The turn came fast. In May 2025 the company's long-serving chief executive stepped down at the wish of the controlling foundation. In July it issued sales and profit warnings, and its shares lost around a fifth of their value in a single day. In September the new chief executive announced about 9,000 job cuts, roughly 11.5 per cent of the global workforce, a large share of them in Denmark 8. By December the shares were on course for the worst year in the company's history as a listed company, having lost about half their value 9.

The causes were commercial rather than scientific: a competitor whose dual-agonist drug was taking share in the American market, a wave of compounded copies that outlived the shortage that had licensed them, and prices under pressure from every direction. At the end of August the Danish economy ministry cut its 2025 growth forecast from 3 per cent to 1.4 per cent, citing weaker prospects for the pharmaceutical industry alongside American tariffs 7.

Then, in February 2026, the company guided to something it had not reported in years: falling sales. Its outlook for 2026 was a decline of between 5 and 13 per cent in adjusted sales at constant exchange rates. The reasons it gave were lower realised prices, including under an American most-favoured-nation pricing agreement, the loss of exclusivity for the semaglutide molecule in certain international markets, and intensifying competition 10. In August it raised that outlook to a range of flat to a 6 per cent decline, on stronger demand for a new oral formulation, launches in new markets and early uptake under a new American public coverage scheme 11.

The economy that did not follow the share price

Here is the twist. The ministry's pessimistic forecast of August 2025 turned out to be wrong in the optimistic direction. When Statistics Denmark published its revised figures in June 2026, growth for 2025 stood at 3.5 per cent. And the office drew attention to a change in composition: in 2025, for the first time since 2021, the other industries together contributed more to growth than the pharmaceutical industry alone 2.

There is no contradiction in a share price halving while output keeps growing, though it looks like one. A share price discounts a decade of expected profits; when the market concludes that future prices will be lower and competition fiercer, it marks the company down at once. Output is counted in the present, in volumes adjusted for price, and in 2025 the company was still selling more of its medicines than the year before. The market was pricing the patent cliff and the price war. The statisticians were counting pens.

The dependence had not disappeared, either. It had simply become visible from both sides. The same concentration that lifted the growth rate in 2022 and 2023 was now a known exposure, discussed openly in ministry forecasts and central-bank analyses. That is probably the most durable legacy of the episode: a small, well-run economy learned, in public and with numbers attached, what it means for one molecule's fortunes to be a line item in the national accounts.

Where this story stops

The rest of this cluster follows the money outward — into the compounding boom that ate into sales, the patent expiries that turned one molecule into a generic in some of the world's largest markets, the grey market that grew wherever the legitimate supply was expensive or absent, and the argument over who should pay for a medicine that a large share of adults are eligible for. Each of those is a story about price. This one has been a story about proportion.

What none of them settles is the question underneath every figure quoted here: how, exactly, the value of a patent-protected molecule should be apportioned between a head office, a factory, a subsidiary in another country and the owner of the intellectual property. That apportionment decides what gets counted as Danish, what gets taxed where, and how large the column in the national accounts really was. It is a question for national accountants with the supply and use tables open, and it is where a technical article would begin.